Opportunities and pitfalls of cancer imaging in clinical trials

Nature Reviews Clinical Oncology

Volumn 8, Issue 9, 2011, Pages 517-527

  Morgan, Bruno ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB;

BLADDER CANCER; BOLD SIGNAL; BRAIN CANCER; BREAST CANCER; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG CLEARANCE; ECHOGRAPHY; HUMAN; LIVER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOGRAPHY; RECTUM CANCER; REVIEW; SOLID TUMOR;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS;

EID: 80052228530     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.62     Document Type: Review

References (120)

1. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
2. Tuma, R. S. Sometimes size doesn't matter: Reevaluating RECIST and tumor response rate endpoints. J. Natl Cancer Inst. 98, 1272-1274 (2006).
3. Husband, J. E. et al. Evaluation of the response to treatment of solid tumours-A consensus statement of the International Cancer Imaging Society. Br. J. Cancer 90, 2256-2260 (2004). (Pubitemid 38961886)
4. Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15, 257-260 (2004). (Pubitemid 38262625)
5. Macdonald, D. R., Cascino, T. L., Schold, S. C. Jr, & Cairncross, J. G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990). (Pubitemid 20195640)
6. Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579-586 (2007). (Pubitemid 350002966)
7. Ratain, M. J. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006). (Pubitemid 46630627)
8. Thiesse, P. et al. Response rate accuracy in oncology trials: Reasons for interobserver variability. J. Clin. Oncol. 15, 3507-3514 (1997). (Pubitemid 27527724)
9. Schwartz, L. H. et al. Evaluation of tumor measurements in oncology: Use of film-based and electronic techniques. J. Clin. Oncol. 18, 2179-2184 (2000). (Pubitemid 30324371)
10. Marcus, C. D. et al. Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives. Crit. Rev. Oncol. Hematol. 72, 217-238 (2009).
11. Buyse, M. et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-Analysis. Lancet 356, 373-378 (2000). (Pubitemid 30487493)
12. George, S. L. Response rate as an endpoint in clinical trials. J. Natl Cancer Inst. 99, 98-99 (2007).
13. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). (Pubitemid 38702844)
14. Benjamin, R. S. et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol. 25, 1760-1764 (2007). (Pubitemid 46797958)
15. Gerstner, E. R., McNamara, M. B., Norden, A. D., Lafrankie, D. & Wen, P. Y. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J. Neurooncol. 94, 97-101 (2009).
16. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
17. Boppudi, S., Wickremesekera, S. K., Nowitz, M. & Stubbs, R. Evaluation of the role of CT in the assessment of response to selective internal radiation therapy in patients with colorectal liver metastases. Australas. Radiol. 50, 570-577 (2006). (Pubitemid 44748082)
18. Dancey, J. E. et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur. J. Cancer 45, 281-289 (2009).
19. Drevs, J. et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and flood flow in a murine renal cell carcinoma model. Cancer Res. 60, 4819-4824 (2000).
20. Murphy, P. S. et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br. J. Cancer 90, 781-786 (2004). (Pubitemid 38406586)
21. Meisamy, S. et al. Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting response with in vivo 1H MR spectroscopy-A pilot study. Radiology 233, 424-431 (2004). (Pubitemid 39423801)
22. Kato, Y., Okollie, B. & Artemov, D. Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn. Reson. Med. 55, 755-761 (2006).
23. Golman, K. et al. Molecular imaging using hyperpolarized 13C. Br. J. Radiol. 76, S118-S127 (2003). (Pubitemid 39530305)
24. van Laarhoven, H. W. M. et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed. 20, 128-140 (2007).
25. Lee, C. P. et al. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br. J. Cancer 101, 1860-1868 (2009).
26. Padhani, A. R. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia 11, 102-125 (2009).
27. Dzik-Jurasz, A. The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research: 2002 Sir Godfrey Hounsfield lecture delivered at the President's Day, Manchester. Br. J. Radiol. 77, 296-307 (2004). (Pubitemid 38579113)
28. Thoeny, H. C. et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin A-4-phosphate after repeated administration. Neoplasia 7, 779-787 (2005).
29. Hoskin, P. J. et al. Hypoxia in prostate cancer: Correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int. J. Radiat. Oncol. Biol. Phys. 68, 1065-1071 (2007). (Pubitemid 47048571)
30. O'Connor, J. P. B. et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: A potential novel biomarker of oxygenation changes in solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 75, 1209-1215 (2009).
31. Barrett, T., Brechbiel, M., Bernardo, M. & Choyke, P. L. MRI of tumor angiogenesis. J. Magn. Reson. Imaging 26, 235-249 (2007). (Pubitemid 47257720)
32. Taylor, N. J. et al. BOLD MRI of human tumor oxygenation during carbogen breathing. J. Magn. Reson. Imaging 14, 156-163 (2001).
33. Venkatesh, S. K. et al. MR elastography of liver tumors: Preliminary results. AJR Am. J. Roentgenol. 190, 1534-1540 (2008). (Pubitemid 351798532)
34. Kurki, T., Lundbom, N., Kalimo, H. & Valtonen, S. MR classification of brain gliomas: Value of magnetization transfer and conventional imaging. Magn. Reson. Imaging 13, 501-511 (1995).
35. Virendra, K. et al. Evaluation of the role of magnetization transfer imaging in prostate: A preliminary study. Magn. Reson. Imaging 26, 644-649 (2008).
36. Warmuth, C., Gunther, M. & Zimmer, C. Quantification of blood flow in brain tumors: Comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 228, 523-532 (2003). (Pubitemid 36910097)
37. Knopp, M. V. et al. Pathophysiologic basis of contrast enhancement in breast tumors. J. Magn. Reson. Imaging 10, 260-266 (1999). (Pubitemid 29463108)
38. Tofts, P. S. et al. Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J. Magn. Reson. Imaging 10, 223-232 (1999). (Pubitemid 29463104)
39. Buckley, D. L. & Parker, G. J. M. in Dynamic contrast-enhanced magnetic resonance imaging in oncology. (eds. Jackson, A., Buckley, D. L. & Parker, G. J. M.) 69-79 (Springer, New York, 2005).
40. Goh, V. et al. Colorectal tumor vascularity: Quantitative assessment with multidetector CT-do tumor perfusion measurements reflect angiogenesis? Radiology 249, 510-517 (2008).
41. Miles, K. A. Functional CT imaging in oncology. Eur. Radiol. 13 (Suppl. 5), M134-M138 (2003). (Pubitemid 38181047)
42. Dawson, P. in Textbook of contrast media. (eds. Dawson, P., Cosgrove, D. O. & Grainger R. G.) 217-228 (Isis Medical Media Ltd, Oxford, 1999).
43. Evelhoch, J. L. Key factors in the acquisition of contrast kinetic data for oncology. J. Magn. Reson. Imaging 10, 254-259 (1999). (Pubitemid 29463107)
44. Bisdas, S. et al. Dynamic contrast-enhanced CT of head and neck tumors: Comparison of first-pass and permeability perfusion measurements using two different commercially available tracer kinetics models. Acad. Radiol. 15, 1580-1589 (2008).
45. Leach, M. O. et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br. J. Cancer 92, 1599-1610 (2005). (Pubitemid 40756468)
46. Goh, V. & Padhani, A. Imaging tumor angiogenesis: Functional assessment using MDCT or MRI? Abdom. Imaging 31, 194-199 (2006).
47. Brix, G., Bahner, M. L., Hoffmann, U. J., Horvath, A. & Schreiber, W. Regional blood flow capillary permeability, and compartmental volumes: Measurement with dynamic CT-initial experience. Radiology 210, 269-276 (1999). (Pubitemid 29004315)
48. Miles, K. A. Perfusion CT for the assessment of tumour vascularity: Which protocol? Br. J. Radiol. 76 (Suppl. 1), S36-S42 (2003). (Pubitemid 39530314)
49. Leach, M. O. et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 365, 1769-1778 (2005). (Pubitemid 40744657)
50. Galbraith, S. M. et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21, 2831-2842 (2003). (Pubitemid 46621830)
51. Lockhart, A. C. et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J. Clin. Oncol. 28, 207-214 (2010).
52. Wong, C. I. et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J. Clin. Oncol. 27, 4718-4726 (2009).
53. Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J. Clin. Oncol. 21, 3955-3964 (2003). (Pubitemid 46606209)
54. Galbraith, S. M. et al. Effects of 5,6-dimethylxanthenone-4-Acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol. 20, 3826-3840 (2002).
55. Jarnagin, W. R. et al. Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann. Oncol. 20, 1589-1595 (2009).
56. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004). (Pubitemid 38524883)
57. Delille, J. P. et al. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: Noninvasive monitoring with functional MR imaging pilot study. Radiology 228, 63-69 (2003).
58. Mayr, N. A. et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J. Magn. Reson. Imaging 12, 1027-1033 (2000).
59. Kamel, I. R. et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J. Vasc. Interv. Radiol. 17, 505-512 (2006). (Pubitemid 44318722)
60. DeVries, A. F. et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res. 61, 2513-2516 (2001). (Pubitemid 32685831)
61. Lehmann, P. et al. A Comparative study of perfusion measurement in brain tumours at 3 Tesla MR: Arterial spin labeling versus dynamic susceptibility contrast-enhanced MRI. Eur. Neurol. 64, 21-26 (2010).
62. Ludemann, L. et al. Brain tumor perfusion: Comparison of dynamic contrast-enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H215O positron emission tomography. Eur. J. Radiol. 70, 465-474 (2009).
63. Wang, M. & Thanou, M. Targeting nanoparticles to cancer. Pharmacol. Res. 62, 90-99 (2010).
64. Neeman, M., Gilad, A. A., Dafni, H. & Cohen, B. Molecular imaging of angiogenesis. J. Magn. Reson. Imaging 25, 1-12 (2007). (Pubitemid 46095196)
65. Daldrup-Link, H. E. et al. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: Initial phase II multicenter trial. Radiology 229, 885-892 (2003). (Pubitemid 37467597)
66. Sosnovik, D. E. & Weissleder, R. Emerging concepts in molecular MRI. Curr. Opin. Biotechnol. 18, 4-10 (2007). (Pubitemid 46227964)
67. Lassau, N. et al. Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest. Radiol. 36, 50-55 (2001). (Pubitemid 32064170)
68. Lassau, N. et al. Dynamic contrast-enhanced ultrasonography (DCE-US): A new tool for the early evaluation of antiangiogenic treatment. Target. Oncol. 5, 53-58 (2010).
69. Lamuraglia, M. et al. Clinical relevance of contrast-enhanced ultrasound in monitoring anti-Angiogenic therapy of cancer: Current status and perspectives. Crit. Rev. Oncol. Hematol. 73, 202-212 (2010).
70. Lassau, N. et al. Gastrointestinal stromal tumors treated with imatinib: Monitoring response with contrast-enhanced sonography. AJR Am. J. Roentgenol. 187, 1267-1273 (2006). (Pubitemid 44630831)
71. Lamuraglia, M. et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur. J. Cancer 42, 2472-2479 (2006). (Pubitemid 44442955)
72. Averkiou, M. et al. Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy. Ultrasound Med. Biol. 36, 68-77 (2010).
73. De, G. U., Aliberti, C., Benea, G., Conti, M. & Marangolo, M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin. Cancer Res. 11, 6171-6176 (2005). (Pubitemid 41262944)
74. Ellegala, D. B. et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to avβ3. Circulation 108, 336-341 (2003). (Pubitemid 36899026)
75. Rapoport, N., Gao, Z. G. & Kennedy, A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl Cancer Inst. 99, 1095-1106 (2007). (Pubitemid 47241394)
76. Alavi, A., Kung, J. W. & Zhuang, H. M. Implications of PET-based molecular imaging on the current and future practice of medicine. Semin. Nucl. Med. 34, 56-69 (2004). (Pubitemid 38056404)
77. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2, 683-693 (2002). (Pubitemid 37328919)
78. Gillies, R. J., Raghunand, N., Karczmar, G. S. & Bhujwalla, Z. M. MRI of the tumor microenvironment. J. Magn. Reson. Imaging 16, 430-450 (2002). (Pubitemid 35167878)
79. Spaepen, K. et al. [18F]FDG PET monitoring of tumour response to chemotherapy: Does [18F]FDG uptake correlate with the viable tumour cell fraction? Eur. J. Nucl. Med. Mol. Imaging 30, 682-688 (2003). (Pubitemid 36612950)
80. Van den Abbeele, A. D. & Badawi, R. D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer 38 (Suppl. 5), S60-S65 (2002).
81. Shankar, L. K. et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J. Nucl. Med. 47, 1059-1066 (2006). (Pubitemid 46939960)
82. Stroobants, S. et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 39, 2012-2020 (2003). (Pubitemid 37297757)
83. Juweid, M. E. et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol. 25, 571-578 (2007). (Pubitemid 350002965)
84. Harry, V. N., Semple, S. I., Parkin, D. E. & Gilbert, F. J. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol. 11, 92-102 (2010).
85. Pomper, M. G. in Cancer, Principles & Practice of Oncology. (eds. DeVita, V. T., Hellman, S. & Rosenberg, S. A.) 679-689 (Lippincott Williams & Wilkins, 2001).
86. Sugawara, Y., Zasadny, K. R., Kison, P. V., Baker, L. H. & Wahl, R. L. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J. Nucl. Med. 40, 1456-1462 (1999). (Pubitemid 29428927)
87. McDermott, S. & Skehan, S. J. Whole body imaging in the abdominal cancer patient: Pitfalls of PET-CT. Abdom. Imaging 35, 55-69 (2010).
88. Pantaleo, M. A. et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat. Rev. 34, 103-121 (2008). (Pubitemid 351372886)
89. Nanni, C., Fantini, L., Nicolini, S. & Fanti, S. Non FDG PET. Clin. Radiol. 65, 536-548 (2010).
90. Shields, A. F. et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4, 1334-1336 (1998). (Pubitemid 28512118)
91. Anderson, H. L. et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21, 2823-2830 (2003). (Pubitemid 46621829)
92. Herbst, R. S. et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 20, 3804-3814 (2002).
93. Rajendran, J. G. & Krohn, K. A. Imaging hypoxia and angiogenesis in tumors. Radiol. Clin. North Am. 43, 169-187 (2005). (Pubitemid 40326567)
94. Gagel, B. et al. [18F]-fluoromisonidazole and [18F]-fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: A feasibility study. BMC Cancer 6, 51 (2006).
95. Collingridge, D. R. et al. The development of [124I]-iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 62, 5912-5919 (2002). (Pubitemid 35204754)
96. Dijkers, E. C. et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87, 586-592 (2010).
97. Jayson, G. C. et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J. Natl Cancer Inst. 94, 1484-1493 (2002). (Pubitemid 35251753)
98. Propper, D. J. et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J. Clin. Oncol. 21, 203-210 (2003). (Pubitemid 46606148)
99. Bland, J. M. & Altman, D. G. Statistical methods for assessing agreement between 2 methods of clinical measurement. Lancet 1, 307-310 (1986). (Pubitemid 16134762)
100. Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50 (Suppl. 1), S122-S150 (2009).
101. Ng, C. S. et al. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: Effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am. J. Roentgenol. 194, W134-W140 (2010).
102. Hopper, K. D. et al. Analysis of interobserver and intraobserver variability in CT tumor measurements. Am. J. Roentgenol. 167, 851-854 (1996). (Pubitemid 26322230)
103. Clarke, L. P. et al. Quantitative imaging for evaluation of response to cancer therapy. Transl. Oncol. 2, 195-197 (2009).
104. Jackson, A., O'Connor, J. P., Parker, G. J. & Jayson, G. C. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin. Cancer Res. 13, 3449-3459 (2007). (Pubitemid 46955104)
105. Gillies, R. J., Anderson, A. R., Gatenby, R. A. & Morse, D. L. The biology underlying molecular imaging in oncology: From genome to anatome and back again. Clin. Radiol. 65, 517-521 (2010).
106. Mankoff, D. A. et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J. Nucl. Med. 44, 1806-1814 (2003). (Pubitemid 39663314)
107. Tateishi, U. et al. Lung tumors evaluated with FDG-PET and dynamic CT: The relationship between vascular density and glucose metabolism. J. Comput. Assist. Tomogr. 26, 185-190 (2002). (Pubitemid 34233362)
108. Bystrom, P. et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann. Oncol. 20, 1057-1061 (2009).
109. Scappaticci, F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20, 3906-3927 (2002).
110. Nilsen, L., Fangberget, A., Geier, O., Olsen, D. R. & Seierstad, T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol. 49, 354-360 (2010).
111. Lankester, K. J. et al. Conventional cytotoxic chemotherapy agents do not have acute antivascular effects, as measured by dynamic contrast enhanced MRI (DCE-MRI) [abstract]. Proc. Am. Soc. Clin. Oncol. 22, a588 (2003).
112. Cheson, B. The case against heavy PETing. J. Clin. Oncol. 27, 1742-1743 (2009).
113. Choi, H. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am. J. Roentgenol. 183, 1619-1628 (2004). (Pubitemid 44210530)
114. Jayson, G. C. et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 23, 973-981 (2005). (Pubitemid 46202317)
115. Jain, R. K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
116. Bryant, A. S., Cerfolio, R. J., Klemm, K. M. & Ojha, B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small-cell lung cancer. Ann. Thorac. Surg. 82, 417-422 (2006).
117. Cerfolio, R. J. et al. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. J. Thorac. Cardiovasc. Surg. 137, 605-609 (2009).
118. Quirk, M. E., Letendre, A. J., Ciottone, R. A. & Lingley, J. F. Anxiety in patients undergoing MR imaging. Radiology 170, 463-466 (1989). (Pubitemid 19035674)
119. LoRusso, P. M. Phase 0 clinical trials: An answer to drug development stagnation? J. Clin. Oncol. 27, 2586-2588 (2009).
120. Dancey, J. E. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 16, 1745-1755 (2010).